Skip to content
value.today

Apellis Pharmaceuticals, Inc.

🇺🇸 Louisville, Kentucky, USAPharmaceuticalsFounded 2009
Total raised
$107 M
6 rounds on record
Latest round
$20 M
Aug 2017
First round on record
May 2010
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Apellis Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2017$20 MNo. 6$10 to $50 million

Apellis Pharmaceuticals, Inc.: Raise no. 6, Aug 2017

Investors in this round

16 investors had bought by the notice of Aug 17, 2017: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Apellis Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $60 M offered; $40 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cedric Francois · Executive Officer, Director
  • Daniel Sinclair Geffken · Executive Officer
  • David Sinclair Watson · Executive Officer
  • Nicole Sinclair Perry · Executive Officer
  • Pascal Deschatelets · Executive Officer
  • Robert Sinclair Kim · Executive Officer
  • Steven Sinclair Axon · Executive Officer
  • A. Sinclair Dunlop · Director
  • Alec Sinclair Machiels · Director
  • Bihua Sinclair Chen · Director
  • Gerald Sinclair Chan · Director
  • Maha Sinclair Katabi · Director
  • Robert Sinclair Adelman · Director
  • Stephanie Sinclair O'Brien · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Cedric Francois, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 17, 2017. Read the notice at the SEC.

equitySEC
Dec 2015$47 MNo. 5$10 to $50 million

Apellis Pharmaceuticals, Inc.: Raise no. 5, Dec 2015

Investors in this round

7 investors had bought by the notice of Feb 8, 2016: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Apellis Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$47 M of $47 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cedric Francois · Executive Officer, Director
  • Daniel Sinclair Geffken · Executive Officer
  • David Sinclair Watson · Executive Officer
  • Federico Sinclair Grossi · Executive Officer
  • Nicole Sinclair Perry · Executive Officer
  • Pascal Deschatelets · Executive Officer
  • A. Sinclair Dunlop · Director
  • Alec Sinclair Machiels · Director
  • Bihua Sinclair Chen · Director
  • Gerald Sinclair Chan · Director
  • Robert Sinclair Adelman · Director
  • Stephanie Sinclair O'Brien · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Cedric Francois, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Feb 8, 2016. Read the notice at the SEC.

equitySEC
Dec 2014$18 MNo. 4$10 to $50 million

Apellis Pharmaceuticals, Inc.: Raise no. 4, Dec 2014

Investors in this round

1 investor had bought by the notice of Jun 9, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Apellis Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$18 M of $18 M offered
Smallest investment taken
$10,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cedric Francois · Executive Officer, Director
  • Pascal Deschatelets · Executive Officer
  • A. Sinclair Dunlop · Director
  • Alec Sinclair Machiels · Director
  • Gerald Sinclair Chan · Director
  • Stephanie Sinclair O'Brien · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Cedric Francois, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jun 9, 2015. Read the notice at the SEC.

equitySEC
Jul 2013$18 MNo. 3$10 to $50 million

Apellis Pharmaceuticals, Inc.: Raise no. 3, Jul 2013

Investors in this round

25 investors had bought by the notice of Aug 27, 2014: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Apellis Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$18 M of $24 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cedric Francois · Executive Officer, Director
  • Pascal Deschatelets · Executive Officer
  • Alec Machiels · Director
  • Gerald Chan · Director
  • Stephanie O'Brien · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Pascal Deschatelets, Chief Operating Officer. Source: SEC Form D and 1 amendment, newest notice filed Aug 27, 2014. Read the notice at the SEC.

equitySEC
May 2011$3 MNo. 2$2 to $10 million

Apellis Pharmaceuticals, Inc.: Raise no. 2, May 2011

Investors in this round

15 investors had bought by the notice of Jun 20, 2011: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Apellis Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $4 M offered; $1 M still to sell
Smallest investment taken
$20,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cedric Francois · Executive Officer, Director
  • Pascal Deschatelets · Executive Officer, Director
  • Alec Machiels · Director
  • David Darst · Director
  • Douglas Onsi · Director
  • Marie-Claude Bernal · Director
  • Sinclair Dunlop · Director
  • Stephen Gillies · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Pascal Deschatelets, Secretary/Director. Source: SEC Form D and 1 amendment, newest notice filed Jun 20, 2011. Read the notice at the SEC.

equitySEC
May 2010$2 MNo. 1Under $2 million

Apellis Pharmaceuticals, Inc.: Raise no. 1, May 2010

Investors in this round

6 investors had bought by the notice of May 21, 2010: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Apellis Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $6 M offered; $4 M still to sell
Smallest investment taken
$50,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cedric Francois · Executive Officer, Director
  • Pascal Deschatelets · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Pascal Deschatelets, Secretary/Director. Source: SEC Form D, newest notice filed May 21, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Apellis Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2017).

    SEC Form D · Aug 2017

  • Revenue range over time, as stated in its notices: no revenue in 2010; no revenue in 2011; revenue of up to $1 million in 2015.

    SEC Form D (revenue range) · Jun 2015

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Aug 2017

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Apellis Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
AJU IB Investment Co., Ltd.Fund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Cormorant Asset Management, LPFund or asset managernot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Cormorant Global Healthcare Master Fund, LPFund or asset managernot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Cormorant Private Healthcare Fund I, LPFund or asset managernot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Hillhouse Capital Management, Ltd.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Michael E. GellertPersonnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Morningside Venture Investments LtdVenture capitalnot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2017)SEC Form 3
venBio Global Strategic Fund II L.P.Fund or asset managernot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2017)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 25 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Apellis Pharmaceuticals, Inc.
NameRoleNamed in
Cedric FrancoisExecutive officerAug 2017
Daniel Sinclair GeffkenExecutive officerAug 2017
David Sinclair WatsonExecutive officerAug 2017
Nicole Sinclair PerryExecutive officerAug 2017
Pascal DeschateletsExecutive officerAug 2017
Robert Sinclair KimExecutive officerAug 2017
Steven Sinclair AxonExecutive officerAug 2017
Federico Sinclair GrossiExecutive officerFeb 2016
A. Sinclair DunlopDirectorAug 2017
Alec Sinclair MachielsDirectorAug 2017
Bihua Sinclair ChenDirectorAug 2017
Cedric FrancoisDirectorAug 2017
Gerald Sinclair ChanDirectorAug 2017
Maha Sinclair KatabiDirectorAug 2017
Robert Sinclair AdelmanDirectorAug 2017
Stephanie Sinclair O'BrienDirectorAug 2017
Alec MachielsDirectorAug 2014
Gerald ChanDirectorAug 2014
Stephanie O'BrienDirectorAug 2014
David DarstDirectorJun 2011
Douglas OnsiDirectorJun 2011
Marie-Claude BernalDirectorJun 2011
Pascal DeschateletsDirectorJun 2011
Sinclair DunlopDirectorJun 2011
Stephen GilliesDirectorJun 2011